32
326030.KO Sk Biopharmaceuticals Co Ltd
- Market cap
- KRW 7.10T
- P/E
- 15.8x
- P/B
- 6.08x
- ROE
- 37.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 326030.KO undervalued?
Graham number326030.KO trades 106.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sk Biopharmaceuticals Co Ltd fundamental analysis
No fundamental analysis for Sk Biopharmaceuticals Co Ltd yet.
Sk Biopharmaceuticals Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SK…
Full company profileSk Biopharmaceuticals Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sk Biopharmaceuticals Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 89.9B | 85.3B | 1.10B | 124B | 26.0B | 419B | 246B | 355B | 548B | 707B | 951B |
| Gross Profit | 11.1B | 3.57B | 1.10B | 123B | 24.0B | 396B | 208B | 321B | 504B | 664B | 892B |
| Operating Income | -57.7B | -98.0B | -139B | -79.3B | -239B | 95.0B | -131B | -37.5B | 96.3B | 204B | 374B |
| EBITDA | - | -93.6B | -134B | -76.4B | -225B | 83.9B | -126B | -20.3B | 101B | 176B | 408B |
| Net Income | -30.4B | -97.6B | -138B | -71.5B | -247B | 64.8B | -139B | -32.9B | 241B | 267B | 380B |
| EPS | - | -1,155 | -1,633 | -846 | -3,159 | 828 | -1,780 | -420 | 3,074 | 3,409 | 4,858 |
| Balance Sheet | |||||||||||
| Total Assets | 194B | 98.4B | 95.5B | 139B | 500B | 644B | 664B | 723B | 1.04T | 1.20T | 1.42T |
| Total Liabilities | 46.2B | 51.1B | 36.9B | 152B | 121B | 199B | 348B | 402B | 463B | 372B | 397B |
| Shareholders' Equity | 148B | 47.2B | 58.6B | -13.0B | 379B | 444B | 317B | 284B | 546B | 813B | 1.02T |
| Cash & Short-term Investments | 38.6B | 25.3B | 74.3B | 51.1B | 59.3B | 226B | 104B | 240B | 323B | 308B | 380B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -48.9B | -98.3B | -141B | -81.3B | -211B | -92.9B | -160B | -94.2B | 94.9B | 176B | 192B |
| Capital Expenditure | 8.80B | 1.65B | 1.44B | 14.0B | 11.0B | 4.32B | 4.91B | 3.25B | 13.4B | 29.5B | 7.71B |
| Free Cash Flow | - | -100.0B | -143B | -95.4B | -225B | -98.9B | -166B | -97.5B | 81.5B | 147B | 184B |
| Ratios | |||||||||||
| ROE | -20.6% | -206.7% | -235.5% | - | -65.3% | 14.6% | -44.0% | -11.6% | 44.1% | 32.8% | 37.2% |
| ROA | -15.7% | -99.3% | -144.5% | -51.4% | -49.5% | 10.1% | -21.0% | -4.5% | 23.2% | 22.3% | 26.8% |
| Net Profit Margin | -33.8% | -114.5% | -12,568.6% | -57.7% | -951.6% | 15.5% | -56.6% | -9.3% | 44.0% | 37.8% | 40.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sk Biopharmaceuticals Co Ltd dividends
Sk Biopharmaceuticals Co Ltd has not paid dividends in the last 9 fiscal years.
Who owns Sk Biopharmaceuticals Co Ltd
- Insiders 50.20%
- Institutions 11.65%
- Public & others 38.15%
- Shares outstanding 78.3M
- Free float 39.0M
Sk Biopharmaceuticals Co Ltd company profile
- Company name
- Sk Biopharmaceuticals Co Ltd
- Ticker
- 326030.KO
- ISIN
- KR7326030004
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 246
- Fiscal year end
- December
- Address
- 221, Pangyoyeok-ro, Seongnam-si, South Korea, 13494
- Phone
- 82 31 8093 0114
- Website
- skbp.com
About Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.
Sk Biopharmaceuticals Co Ltd management
4- Mr. Dong Hoon LeeCEO, President & Executive Director · born 1968
- Mr. Jiyoung JungCFO & Executive Director · born 1973
- Dr. Seon-kwan HwangChief Technology Officer
- Dr. Yong-Je ShinDirector of RPT Preclinical Center